Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The field moved from single GLP-1 receptor agonism, to dual GIP/GLP-1 agonism, and then to adding a third receptor glucagon to capture an energy-expenditure lever on top of appetite and glucose control
This option is provided with clinical oversight and may be considered as part of a broader treatment approach for weight management
Metabolic Pharmaceuticals ultimately did not pursue Phase 3 trials for obesity, and the company's pipeline shifted toward other indications
A second oral GLP-1 approval is anticipated in the first half of 2026 from Eli Lilly with orforglipron
US$ 23.30
US$ 28.71
US$ 29.71
US$ 26.34
US$ 20.05
US$ 21.65
US$ 24.34
US$ 23.92
US$ 20.37
